🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

On the heels of an exciting ASCO where we presented additional positive data on ADI-001, the team rang the closing bell at NASDAQ today!! It’s an honor to see so many inspired by our mission to deliver best-in-class gamma-delta T cell therapies for patients fighting cancer.

We’re celebrating #pride at adicet cmru and recognizing the important role the LGBTQ+ community has played in building diverse, inclusive and supportive communities. There is more work to be done and we continue to listen, learn and support advances in #diversityandinclusion.

AdicetBio Chief Medical Officer Francesco Galimi, joins global experts to discuss the discovery, manufacturing and development of GD T cells at the 3rd Gamma Delta T Cell Therapies Summit this week! #celltherapy #CART #gammadelta #biotechnology

As our pipeline progresses, we expanded into a new state-of-the-art facility! We look forward to calling this home as we live our mission to deliver best-in-class gamma delta T cell therapies for patients fighting cancer! #Adicetlife #greatplacetowork #celltherapy #biotechnology

When we spend our days developing transformative therapies to defeat cancer, it’s important to take a moment to connect with our colleagues and enjoy the journey! Friendly competition & lots of fun at our Summer party! #Adicetlife #greatplacetowork #celltherapy #biotechnology

AdicetBio CMO Francesco Galimi joins leaders at the 7th Annual CAR-TCR Summit to review the latest developments including the next frontier of gamma delta CAR T cell therapies. #celltherapy #CART #CARTCR #biotechnology #oncology

CEO Chen Schor joined the “Creating a World Without Disease” forum at the Longwood Healthcare Leaders Fall Webconference this week. Together, Chen and other thought leaders collaborated to accelerate the translation of discoveries into medicines to help patients.

Welcome Yining Le, our new VP, Head of Biometrics! We look forward to her playing a crucial role in designing the pivotal studies for lead product candidate ADI-001 and in the analysis of various studies across our deep pipeline. #celltherapy #biotechnology #mycompany

Francesco Galimi joins an expert panel to review emerging cell therapies at the Immuno-Oncology Summit! He will discuss why Gamma Delta T cells are an attractive platform and review ADI-001, the first clinical stage CAR-engineered gamma delta T cell therapy in development.

CSO Blake Aftab Ph.D. joins top researchers & thought leaders at the Prostate Cancer Foundation Scientific Retreat. In a panel reviewing the potential for gamma delta T cell therapies, he'll discuss key progress being made at Adicet with CARs, CAds and PSMA targeting. #PCFRetreat22

Adicet is excited to be on the ground Society for Immunotherapy of Cancer kicking off today in Boston! We’re presenting preclinical data and unveiling 4 new highly differentiated CAR (chimeric antigen receptor) and CAd (chimeric adaptor) pipeline programs targeting several heme and solid malignancies.

Join us tomorrow (Thursday, Nov 10 at 9:00 a.m. ET) for our R&D Day where we’ll be unveiling details on four new highly differentiated CAR and CAd pipeline candidates! Live Webcast link in Investor “Presentations & Events” section at adicetbio.com.

Congratulations to Marissa Herrman & the Adicet research team for being selected as this year’s Journal for ImmunoTherapy of Cancer Best Immune Cell Therapies and Immune Cell Engineering Paper! Your commitment to developing transformative therapies to defeat cancer is inspiring! #celltherapy #SITC2022

CMO, Francesco Galimi joined top experts in the field to review “Winning Strategies” for advancing potential oncology cell therapies at the Protein and Antibody Engineering Summit this week! #celltherapy #oncology #gammadelta #CART

We are pleased to announce Nancy Boman as our new SVP, Chief Regulatory Officer! Nancy will play a crucial role as we advance our novel pipeline of CAR and CAd gamma delta T cell therapies. #biotechnology #celltherapy # CART #oncology

Congrats Kevin Nishimoto & Adicet researchers for being selected by ASI (Australian Society for Immunology) as one of the top 10 articles of 2022 published in Clinical & Translational Immunology (CTI) & featured in the "Best of ICB & CTI Session” at the ASI 2022 conference!

AdicetBio announces positive clinical data including continued complete responses across dose levels and six-month durability for ADI-001 at #ASH2022! investor.adicetbio.com/news-releases/… #celltherapy #CART #biotechnology #oncology

During Women's History Month, we honor the impact women have made in our industry and beyond. We thank all of the women at Adicet and on the frontlines of biopharma innovation & patient care for their inspiring contributions. #womenshistorymonth #diversity #inclusion

We are pleased to announce Shon Green, Ph.D, as our new Vice President of Nonclinical Development! Shon will play a crucial role as we advance our novel pipeline of CAR and CAd gamma delta T cell therapies. #biotechnology #celltherapy #CART #oncology

We're honored for AdicetBio CSO, Blake Aftab Ph.D.'s flagship speaking role at the Asia-Pacific Vaccine and Immunotherapy Congress where global experts discuss the latest in #celltherapy & immune-#oncology clinical studies, drug development and more. #APVIC2023 @QIMRBerghofer